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BACKGROUND
Experimental and clinical evidence suggests that cyclosporine may attenuate reper-
fusion injury and reduce myocardial infarct size. We aimed to test whether cyclo-
sporine would improve clinical outcomes and prevent adverse left ventricular re-
modeling.
METHODS
In a multicenter, double-blind, randomized trial, we assigned 970 patients with an 
acute anterior ST-segment elevation myocardial infarction (STEMI) who were under-
going percutaneous coronary intervention (PCI) within 12 hours after symptom 
onset and who had complete occlusion of the culprit coronary artery to receive a 
bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per 
kilogram of body weight) or matching placebo before coronary recanalization. The 
primary outcome was a composite of death from any cause, worsening of heart 
failure during the initial hospitalization, rehospitalization for heart failure, or ad-
verse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was 
defined as an increase of 15% or more in the left ventricular end-diastolic volume.
RESULTS
A total of 395 patients in the cyclosporine group and 396 in the placebo group 
received the assigned study drug and had data that could be evaluated for the 
primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cy-
closporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence 
interval, 0.78 to 1.39; P = 0.77). Cyclosporine did not reduce the incidence of the 
separate clinical components of the primary outcome or other events, including 
recurrent infarction, unstable angina, and stroke. No significant difference in the 
safety profile was observed between the two treatment groups.
CONCLUSIONS
In patients with anterior STEMI who had been referred for primary PCI, intrave-
nous cyclosporine did not result in better clinical outcomes than those with placebo 
and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the 
French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials 
.gov number, NCT01502774; EudraCT number, 2009-013713-99.)
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Over the past three decades, major progress has been made in the treatment of patients with ST-segment elevation 
myocardial infarction (STEMI).1 Nevertheless, the 
rates of death, heart failure, and recurrent ische-
mic events occurring in the first year after in-
farction remain unacceptably elevated in this high-
risk population. Although many advances have 
been made in the development of methods to 
reopen the culprit coronary artery and prevent 
reocclusion, there is currently no specific treat-
ment that targets myocardial reperfusion injury, 
which is a paradoxical form of myocardial dam-
age that occurs as a result of the restoration of 
vessel patency.2 Growing evidence from experi-
mental studies and small-size proof-of-concept 
clinical trials shows that reperfusion injury con-
tributes greatly to the final infarct size.3-5 Pre-
clinical studies indicate that the opening of the 
mitochondrial permeability transition pore (PTP) 
in the inner mitochondrial membrane plays a 
major role in reperfusion injury.6,7 Either genetic 
or pharmacologic inhibition of cyclophilin D, a 
major component of the PTP, reduces the sever-
ity of myocardial reperfusion injury.8-10
Cyclosporine is a pharmacologic inhibitor of 
cyclophilin D. In a proof-of-concept phase 2 trial, 
we found that the administration of cyclosporine 
immediately before primary percutaneous coro-
nary intervention (PCI) reduced the myocardial 
infarct size in patients with STEMI.11 In the cur-
rent phase 3 trial, we investigated whether a 
single intravenous dose of cyclosporine, admin-
istered immediately before PCI, would improve 
clinical outcomes and prevent adverse left ven-
tricular remodeling at 1 year in patients with 
anterior STEMI.
Me thods
Study Design
The Does Cyclosporine Improve Clinical Outcome 
in ST Elevation Myocardial Infarction Patients 
(CIRCUS) trial was an international, investigator-
driven, multicenter, randomized, double-blind, 
placebo-controlled trial, which was coordinated 
by the Hospices Civils de Lyon.12 This trial was 
performed in accordance with the principles of 
the Declaration of Helsinki and the European 
guidelines for Good Clinical Practice. Approval 
was obtained from the ethics committees in the 
relevant countries.
The study was supported by a grant from the 
French Ministry of Health. NeuroVive Pharmaceu-
tical provided the study drug at no charge, as well 
as supplementary funding to allow for the inclu-
sion of study sites in Belgium and Spain. The 
funders had no role in the design of the study, 
the collection, monitoring, analysis, or interpre-
tation of the data, or the writing of the report.
The authors designed and coordinated the 
trial, oversaw the study conduct and reporting, 
managed the database, and wrote all drafts of the 
manuscript. All the authors vouch for the accuracy 
and completeness of the data and the analyses 
reported and for the fidelity of the study to the 
trial protocol, which is available with the full 
text of this article at NEJM.org.
Study Population
Patients eligible for enrollment were men and 
women, 18 years of age or older, who presented 
within 12 hours after the onset of symptoms 
that were consistent with an acute coronary syn-
drome, who had ST-segment elevation of 0.2 mV 
or more in two contiguous anterior leads, and 
for whom the clinical decision was made to treat 
with PCI. It was also required for trial eligibility 
that the culprit coronary artery was the left an-
terior descending coronary artery, with a Throm-
bolysis in Myocardial Infarction (TIMI) flow 
grade of 0 or 1 at the time of diagnostic coro-
nary angiography. Patients with cardiogenic shock 
at admission and those with evidence of coro-
nary collateral vessels (Rentrop score of 2 or 3 for 
the region at risk) on initial coronary angiogra-
phy were excluded. (A Rentrop score of 0 indi-
cates no filling of any collateral channels; 1, fill-
ing by collateral vessels of side branches of the 
artery to be perfused without visualization of 
the epicardial segment; 2, partial filling of the 
epicardial artery by collateral vessels; and 3, 
complete filling of the epicardial artery by col-
lateral vessels.) The complete inclusion and ex-
clusion criteria are provided in the Supplemen-
tary Appendix, available at NEJM.org. All the 
patients provided written informed consent be-
fore inclusion in the study.
PCI and Study Treatment
Patients were randomly assigned, in a 1:1 ratio, 
to receive cyclosporine or placebo (control group). 
Randomization with stratification according to 
study center was performed after the initial coro-
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nary angiography, with the use of a secure 24-
hour computerized central system.
The investigational product was a lipid emul-
sion formulation of cyclosporine (CicloMulsion, 
NeuroVive Pharmaceutical),13 administered intra-
venously at a dose of 2.5 mg per kilogram of 
body weight. The control group received a match-
ing placebo formulation. In each group, the study 
drug was infused over a period of 2 to 3 minutes 
by means of a catheter positioned within an 
antecubital vein, before the PCI procedure.
Patients underwent PCI according to standard 
guidelines.14 The use of thrombus aspiration, 
bare-metal or drug-eluting stents, and glycopro-
tein IIb/IIIa inhibition was left to the discretion 
of the treating physician.
Study Outcomes
Our initial plan was to use the composite of 
death or rehospitalization for heart failure as the 
primary outcome. We estimated that the re-
quired sample would be 3862 patients. Owing to 
limited funding, it was necessary to redesign the 
trial with a smaller sample size. We therefore 
chose to add two additional outcomes to the 
primary composite outcome — worsening of 
heart failure during the initial hospitalization 
and adverse left ventricular remodeling. These 
two components were chosen because there is a 
pathophysiological link among infarct size, ad-
verse left ventricular remodeling, heart failure, 
and survival and because worsening of heart 
failure can be observed after PCI reperfusion in 
patients with STEMI. The decision to revise the 
primary outcome and reduce the necessary 
sample size was taken before the enrollment of 
any patients in the trial. Details are provided in 
the Supplementary Appendix.
The resulting primary efficacy outcome was a 
composite of death from any cause, worsening 
of heart failure during the initial hospitalization 
(i.e., the index STEMI hospitalization for each 
patient), rehospitalization for heart failure, and 
adverse left ventricular remodeling within 1 year. 
The definition of adverse left ventricular remod-
eling was set as an increase of 15% or more in 
the left ventricular end-diastolic volume.15 Defi-
nitions of heart-failure events and echocardio-
graphic methods for the determination of left 
ventricular remodeling are provided in the Sup-
plementary Appendix.
Secondary outcomes included changes in left 
ventricular ejection fraction and left ventricular 
end-diastolic and end-systolic volumes as assessed 
during the initial hospitalization and at 1 year, 
as well as all the individual components of the 
primary outcome, recurrent acute myocardial 
infarction, unstable angina, and stroke. All the 
clinical events were adjudicated by an events-
validation committee whose members were un-
aware of the study-group assignments.
Electrocardiographic and coronary angio-
graphic data were stored digitally and sent to a 
central core laboratory for analysis. The area at 
risk according to angiography was determined at 
baseline and after PCI as described in the Sup-
plementary Appendix. The total creatine kinase 
level was measured locally at admission and at 
4, 12, and 24 hours after reperfusion. Safety 
assessments included the measurement of the 
creatinine and blood glucose levels and the 
white-cell count at baseline and at 48 hours.
Statistical Analysis
We estimated that the event rates in the control 
group over the planned 12 months of the study 
would be 7% for death from any cause and 42% 
for the combined outcome of heart failure or left 
ventricular remodeling. We estimated that 790 
patients (395 patients per group) would be re-
quired for the study to have 80% power to detect 
a 20% lower relative risk in the cyclosporine 
group than in the placebo group, at a two-sided 
alpha level of 5%. From the literature, we esti-
mated that the assessment of left ventricular 
remodeling would be missing for 14% of pa-
tients surviving at 1 year, and the sample size 
was increased to adjust for missing values.15 The 
sample size was increased by a further 10% to 
accommodate the fact that the sample size was 
calculated assuming the use of a chi-square test, 
whereas a different model was used for the 
analysis. The final sample size was estimated to 
be 972 patients. The sample size was calculated 
with the use of nQuery Advisor + nTerim soft-
ware, version 2.0 (Statistical Solutions).
For baseline and procedural characteristics, 
data are presented for all the patients who un-
derwent randomization. For the primary analy-
sis, a modified as-treated analysis was prespeci-
fied to include all the patients who underwent 
randomization, received the study drug, and had 
a valid measurement for the primary outcome. 
A per-protocol analysis was also prespecified. 
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The population for the per-protocol analysis is 
defined in the Supplementary Appendix.
For the primary outcome, we compared the 
proportion of patients in the cyclosporine group 
versus the control group who had at least one 
component event of the primary composite ef-
ficacy outcome at 1 year by using a logistic 
mixed-effect regression model that included treat-
ment as a fixed effect and center as a random 
effect. For each component of the primary out-
come and for secondary clinical outcome events 
such as myocardial infarction, unstable angina, 
and stroke, similar methods were used without 
correction for multiple testing. All the reported 
subgroup analyses were prespecified before the 
database was locked and are listed in the statis-
tical analysis plan (available with the protocol at 
NEJM.org).
R esult s
Characteristics of the Patients, Procedural 
Characteristics, and Hospital Course
From April 2011 through February 2014, a total 
of 970 patients were enrolled at 42 hospitals in 
three countries, with 475 patients assigned to 
the cyclosporine group and 495 to the control 
group. The intention-to-treat analysis included 
all these patients except for 1 in the cyclosporine 
group who did not provide written informed 
consent. Of the 970 patients, 960 (99.0%) re-
ceived the randomized treatment (469 patients 
in the cyclosporine group and 491 in the control 
group). The modified as-treated analysis includ-
ed all the patients who underwent randomiza-
tion, received the study drug, and had a valid 
measurement for the primary outcome (395 pa-
tients in the cyclosporine group and 396 in the 
control group) (Fig. 1). The per-protocol analysis 
included 345 patients in the cyclosporine group 
and 336 patients in the control group.
The baseline characteristics of all the trial 
participants are shown in Table 1, and the pro-
cedural characteristics are shown in Table 2. 
These characteristics were well balanced between 
the two groups, except for the proportion of 
smokers, which was lower in the cyclosporine 
group than in the control group (39.0% vs. 
45.7%, P = 0.03) (Table 1), and the proportion of 
patients with multivessel disease, which was 
higher in the cyclosporine group than in the 
control group (40.9% vs. 33.1%, P = 0.01) (Table 2). 
The size of the area at risk and the proportion of 
patients with a TIMI flow grade of 2 or 3 after 
PCI were similar in the two groups. The baseline 
and procedural characteristics of the modified 
as-treated population (the primary analysis popu-
lation) were also similar in the two groups (Ta-
bles S1 and S2 in the Supplementary Appendix).
The status of the patients with respect to 
clinical heart failure after PCI and the initial 
treatment of the patients in the coronary care 
unit were similar in the two groups (Table S3 in 
the Supplementary Appendix). The medications 
at discharge were also similar in the two groups 
(Table S4 in the Supplementary Appendix).
Creatine Kinase and Electrocardiographic Data
There was no significant between-group differ-
ence in the value of total creatine kinase at any 
time point (Table S5 in the Supplementary Ap-
pendix). The peak value was 3992 IU per liter 
(interquartile range, 1910 to 5447) in the cyclo-
sporine group and 3917 IU per liter (interquar-
tile range, 1878 to 5608) in the control group. 
There was also no significant difference be-
tween the two groups with respect to the extent 
of ST-segment elevation at baseline, after PCI, at 
discharge, or at 1 year (Table S6 in the Supple-
mentary Appendix).
Echocardiographic Data
Echocardiographic data were not available for 74 
of 474 patients (15.6%) in the cyclosporine group 
and for 95 of 495 (19.2%) in the control group, 
owing to missing or poor-quality recordings 
(Fig. 1). There was no significant difference be-
tween the two groups with respect to left ven-
tricular ejection fraction or left ventricular end-
diastolic or end-systolic volumes at any time 
point (Table S7 in the Supplementary Appendix).
Efficacy and Safety
A total of 7 patients were lost to follow-up at 
1 year. A primary outcome event occurred in 233 
of 395 patients (59.0%) in the cyclosporine group 
and in 230 of 396 (58.1%) in the control group 
(odds ratio in the cyclosporine group, 1.04; 95% 
confidence interval [CI], 0.78 to 1.39; P = 0.77) 
(Table 3). All-cause mortality at 1 year was 7.1% 
in the cyclosporine group and 6.6% in the con-
trol group (odds ratio, 1.09; 95% CI, 0.63 to 
1.90; P = 0.76). The rate of initial worsening of 
heart failure or rehospitalization for heart failure 
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at 1 year was similar in the cyclosporine group 
and the control group (22.8% and 22.7%, re-
spectively; odds ratio, 1.01; 95% CI, 0.72 to 1.41; 
P = 0.97). Adverse left ventricular remodeling oc-
curred in 42.8% of the patients in the cyclospo-
rine group and in 40.7% of those in the control 
group (odds ratio, 1.09; 95% CI, 0.82 to 1.46; 
P = 0.53). The combined incidence of death, heart-
failure worsening, and rehospitalization for heart 
failure at 1 year was similar in the two groups 
(Fig. 2). The rates of all other secondary clinical 
outcomes, including cardiogenic shock, recurrent 
myocardial infarction, unstable angina, stroke, 
and acute renal failure, were similar in the two 
groups at 1 year (Table 3).
The results of the per-protocol analysis were 
Figure 1. Randomization of Patients and Inclusion in the Intention-to-Treat, Modified As-Treated, and Per-Protocol 
Analyses.
The intention-to-treat population included all the patients who underwent randomization except for one patient in 
the cyclosporine group who did not provide written informed consent; the modified as-treated population included 
all the patients who underwent randomization, received the study drug, and had a valid measurement for the pri-
mary outcome. The population for the per-protocol analysis is defined in the Supplementary Appendix. Scores on 
the Rentrop classification range from 0 to 3, with higher scores indicating greater degree of collateral circulation. 
A score of 0 indicates no filling of any collateral channels; 1, filling of side branches of the artery to be perfused by 
collateral vessels without visualization of the epicardial segment; 2, partial filling of the epicardial artery by collateral 
vessels; and 3, complete filling of the epicardial artery by collateral vessels. LAD denotes left anterior descending, 
and TIMI Thrombolysis in Myocardial Infarction.
475 Were assigned to cyclosporine 495 Were assigned to placebo
474 Were included in the
 intention-to-treat analysis
970 Patients presenting with acute anterior myocardial
infarction were enrolled and underwent randomization
495 Were included in the
intention-to-treat analysis
395 Were included in the modified
as-treated analysis
396 Were included in the modified
as-treated analysis
345 Were included in the per-protocol
analysis
336 Were included in the per-protocol
analysis
 1 Was excluded owing to
lack of informed consent
99 Were excluded
4 Did not receive any treatment
95 Had missing or poor echo-
cardiographic data
79 Were excluded
1 Was imprisoned and therefore
ineligible
4 Did not receive any treatment
74 Had missing or poor echo-
cardiographic data
50 Were excluded
27 Had initial TIMI flow grade >1
2 Had non-LAD culprit artery
21 Had Rentrop score >1
60 Were excluded
26 Had initial TIMI flow grade >1
1 Had non-LAD culprit artery 
28 Had Rentrop score >1
1 Had cardiogenic shock
at inclusion
1 Was undergoing treatment not
permitted by protocol
3 Received treatment outside the
period specified in protocol
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consistent with those of the modified as-treated 
(primary) analysis (Table S8 in the Supplemen-
tary Appendix). Data for all the outcomes except 
left ventricular remodeling were available for the 
entire intention-to-treat population; there were 
no significant differences between the two groups 
in these analyses (Table S9 and Fig. S1 in the 
Supplementary Appendix).
The primary outcome at 1 year was consistent 
across all the prespecified subgroups except for 
the analysis stratified according to Killip class at 
baseline, for which there was a significant inter-
action between Killip class and treatment effect 
(P = 0.009) (Fig. S2 in the Supplementary Appen-
dix). No adverse effects of cyclosporine therapy 
on renal function, white-cell count, or blood 
glucose level were detected (Table S10 in the 
Supplementary Appendix).
Discussion
In patients who had STEMI with anterior in-
farcts, the intravenous administration of cyclo-
sporine just before PCI did not result in a lower 
risk of the composite primary outcome of death 
from any cause, worsening of heart failure dur-
ing the initial hospitalization, rehospitalization 
for heart failure, or adverse left ventricular re-
modeling than the risk with placebo. Adminis-
tration of cyclosporine also did not result in a 
lower risk of any of the individual components 
of the combined outcome or of any of several 
secondary outcomes.
Several effect modifiers (e.g., TIMI flow grade 
at admission, the duration of ischemia, and the 
timing of drug administration) may attenuate 
the potential clinical benefit of a treatment that 
targets reperfusion injury.17 Coexisting conditions 
(e.g., diabetes) and concomitant treatments (e.g., 
antiplatelet therapy) may also influence reperfu-
sion injury and the response to protective inter-
ventions.18 In the CIRCUS trial, however, we 
found no significant difference in these baseline 
characteristics (apart from smoking) between 
the two groups.19,20 Hence, the lack of an effect 
with cyclosporine is unlikely to be related to the 
influence of any of these effect modifiers or 
coexisting conditions.
Characteristic Cyclosporine (N = 474) Control (N = 495)
Age — yr 60.4±13.1 59.5±12.7
Male sex — no. (%) 399 (84.2) 396 (80.0)
Body-mass index† 26.9±4.3 26.8±4.1
Killip class at admission — no./total no. (%)
I 369/422 (87.4) 381/437 (87.2)
II 45/422 (10.7) 41/437 (9.4)
III 6/422 (1.4) 10/437 (2.3)
IV 2/422 (0.5) 5/437 (1.1)
Current smoking — no. (%) 185 (39.0) 226 (45.7)
Hypertension — no. (%) 178 (37.6) 183 (37.0)
Diabetes mellitus — no. (%)  65 (13.7)  58 (11.7)
Dyslipidemia — no. (%) 186 (39.2) 187 (37.8)
Previous myocardial infarction — no. (%) 28 (5.9) 26 (5.3)
Previous ischemic heart disease — no. (%) 31 (6.5) 32 (6.5)
Treated with CABG — no./total no. (%) 1/31 (3.2) 0/32
Treated with PCI — no./total no. (%) 26/31 (83.9) 25/32 (78.1)
Managed medically — no./total no. (%) 4/31 (12.9) 7/32 (21.9)
Previous heart failure — no. (%)  1 (0.2) 5 (1.0)
*  Plus–minus values are means ±SD. There were no significant between-group differences in any of the characteristics 
listed, except for current smoking (P = 0.03). CABG denotes coronary-artery bypass grafting, and PCI percutaneous cor-
onary intervention.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Characteristics of the Patients at Baseline.*
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Characteristic Cyclosporine (N = 474) Control (N = 495)
Time from symptom onset to hospital arrival — hr 3.4±3.0 3.4±3.1
Time from hospital arrival to treatment administration — hr 1.0±1.3 1.1±1.7
Total ischemic time
Duration — hr† 4.4±3.0 4.5±2.9
Distribution — no./total no. (%)
<2 hr 54/432 (12.5) 42/446 (9.4)
2–6 hr 306/432 (70.8) 307/446 (68.8)
>6 hr 72/432 (16.7) 97/446 (21.7)
Prehospital thrombolysis — no./total no. (%) 28/474 (5.9) 32/493 (6.5)
Medication from first medical care to PCI — no./total no. (%)‡
Heparin 388/474 (81.9) 408/493 (82.8)
Glycoprotein IIb/IIIa inhibitor 181/474 (38.2) 185/493 (37.5)
Loading dose of P2Y12 inhibitor 428/474 (90.3) 435/493 (88.2)
Aspirin 445/474 (93.9) 453/493 (91.9)
Morphine 284/474 (59.9) 270/493 (54.8)
Site of occlusion in left anterior descending artery — no. (%)
Proximal or main left artery 214 (45.1) 203 (41.0)
Medial or distal segment or diagonal branch 260 (54.9) 292 (59.0)
Multivessel disease — no. (%) 194 (40.9) 164 (33.1)
Thrombus burden ≥3 — no./total no. (%) 311/447 (69.6) 315/483 (65.2)
Rentrop score of 2 or 3 — no./total no. (%)§ 29/446 (6.5) 36/483 (7.5)
Area at risk — %¶ 36.5±8.4 36.1±8.6
TIMI flow grade before PCI — no./total no. (%)‖
0 359/446 (80.5) 395/483 (81.8)
1 55/446 (12.3) 55/483 (11.4)
2 21/446 (4.7) 27/483 (5.6)
3 11/446 (2.5) 6/483 (1.2)
Thrombus aspiration — no. (%) 359 (75.7) 377 (76.2)
Stenting — no. (%) 422 (89.0) 434 (87.7)
No reflow observed on angiography — no. (%) 27 (5.7) 28 (5.7)
TIMI flow grade after PCI — no./total no. (%)
0 6/466 (1.3) 7/487 (1.4)
1 5/466 (1.1) 5/487 (1.0)
2 33/466 (7.0) 25/487 (5.1)
3 422/466 (90.6) 450/487 (92.4)
*  Plus–minus values are means ±SD. There were no significant between-group differences in any of the characteristics 
listed, except for multivessel disease (P = 0.01). TIMI denotes Thrombolysis in Myocardial Infarction.
†  Data were missing for 42 patients in the cyclosporine group and for 49 in the control group.
‡  Heparin was low-molecular-weight heparin or unfractionated heparin. P2Y12 inhibitors included clopidogrel, prasugrel, 
and ticagrelor.
§  Scores on the Rentrop classification range from 0 to 3, with higher scores indicating greater degree of collateral circulation. 
A score of 0 indicates no filling of any collateral channels; 1, filling of side branches of the artery to be perfused by collateral 
vessels without visualization of the epicardial segment; 2, partial filling of the epicardial artery by collateral vessels; and 3, 
complete filling of the epicardial artery by collateral vessels. Local investigators could not always accurately assess Rentrop 
scores in emergency settings, so some patients with a Rentrop score of 2 or 3 were included in the trial. This situation was 
corrected at the end of the trial by the centralized, blinded analysis and was taken into account by the per-protocol analysis.
¶  The area at risk was assessed by means of the Alberta Provincial Project for Outcome Assessment in Coronary Heart 
Disease (APPROACH) score.16 The APPROACH score is a scoring system in which the left ventricle is divided into re-
gions defined by the distribution of perfusion of each coronary artery, and the estimated amount of myocardium in 
each region is used to calculate the amount of jeopardized myocardium for a given site of vessel occlusion. The area at 
risk is expressed as the percent of the left ventricular mass.
‖  Some patients with a TIMI flow grade of 2 or 3 were included by local investigators, which was a protocol deviation. All 
coronary angiograms were read centrally by persons who were unaware of the study-group assignments, and the situa-
tion was taken into account in the per-protocol analysis.
Table 2. Procedural Characteristics.*
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One important limitation of this trial is that 
we included in the primary outcome the non-
clinical outcome of adverse left ventricular re-
modeling, which accounted for a substantial 
proportion of the primary outcome rate. Left 
ventricular remodeling is a surrogate outcome 
— one that was not successfully measured in 
17.4% of the trial participants. However, in sec-
ondary analyses, no beneficial effect of cyclo-
sporine was detected on any of the hard clinical 
outcomes.
Unlike our previous smaller, phase 2 trial,11 
the CIRCUS trial showed no benefit of cyclospo-
rine in reducing the peak release of creatine ki-
nase, a crude estimate of infarct size. This dif-
ference may be related to a limited use of direct 
stenting in the CIRCUS trial or possibly to a 
higher rate of thrombus aspiration observed in 
this trial, the inclusion of only patients with 
anterior infarcts, or a higher rate of use of load-
ing doses of P2Y12 inhibitors, which reduce in-
farct size.11,21 The formulation of cyclosporine 
may also play a confounding role. In our previ-
ous trial, we used Sandimmune (Novartis), 
whereas in the current trial we used CicloMul-
sion. The vehicle of Sandimmune (Cremophor EL 
[polyoxyethylated castor oil]) differs from that of 
CicloMulsion (lipid emulsion), and both have 
been shown to alter mitochondrial respiration 
and PTP opening in a different manner, possibly 
influencing infarct size.22,23 Whether the vehicles 
contributed to the discrepancy between the two 
studies remains to be clarified. However, unpub-
lished data from our group indicate that Ciclo-
Mulsion is associated with a significant reduc-
tion in infarct size in the mouse heart. Previous 
preclinical and clinical studies evaluating the 
effects of cyclosporine against reperfusion injury 
have shown varied results.24-31 Cyclosporine is 
not a specific inhibitor of PTP opening, and its 
nonmitochondrial effects might have attenuated 
a potential benefit of inhibition of PTP opening.
Almost one of four patients in the current 
trial died or was hospitalized for heart failure 
despite receiving state-of-the-art medical care. 
This finding is a reminder of the substantial 
residual risk in this population and the persis-
tent room for improvement in the medical treat-
ment of high-risk patients with STEMI.32 The 
results of this trial do not challenge the concept 
that reperfusion injury is clinically important. 
Recent phase 2 trials that have used either ische-
mic or pharmacologic postconditioning suggest 
that interventions applied at the time of reper-
fusion can limit infarct size and improve func-
tional recovery.4,20,33 Their effect on clinical 
Outcome
Cyclosporine 
(N = 395)
Control 
(N = 396)
Odds Ratio 
(95% CI) P Value
number (percent)
Primary composite outcome* 233 (59.0) 230 (58.1) 1.04 (0.78−1.39) 0.77
Death from any cause 28 (7.1) 26 (6.6) 1.09 (0.63−1.90) 0.76
Cardiovascular death 24 (6.1) 24 (6.1) 1.01 (0.56−1.81) 0.98
Heart-failure worsening or rehospital-
ization for heart failure
90 (22.8) 90 (22.7) 1.01 (0.72−1.41) 0.97
Heart-failure worsening 62 (15.7) 67 (16.9) 0.92 (0.63−1.34) 0.65
Rehospitalization for heart failure 42 (10.6) 41 (10.4) 1.03 (0.65−1.63) 0.89
Left ventricular remodeling 169 (42.8) 161 (40.7) 1.09 (0.82−1.46) 0.53
Cardiogenic shock 26 (6.6) 24 (6.1) 1.09 (0.61−1.94) 0.77
Recurrent myocardial infarction 9 (2.3) 15 (3.8) 0.59 (0.26−1.37) 0.22
Stroke 7 (1.8) 12 (3.0) 0.58 (0.22−1.48) 0.25
Major bleeding 7 (1.8) 9 (2.3) 0.73 (0.27−2.00) 0.54
*  The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospital-
ization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year.
Table 3. Clinical Outcomes at 1 Year in the Modified As-Treated Population.
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on October 18, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;11 nejm.org September 10, 2015 1029
Cyclosporine in Acute Myocardial Infarction
outcome remains to be determined in phase 3 
studies.
In conclusion, among patients with anterior 
STEMI who were referred for primary PCI, we 
compared the intravenous administration of cy-
closporine at a dose of 2.5 mg per kilogram just 
before PCI with placebo. Cyclosporine did not 
reduce the risk of the composite outcome of 
death from any cause, worsening of heart failure 
during the initial hospitalization, rehospitaliza-
tion for heart failure, or adverse left ventricular 
remodeling at 1 year.
Supported by grants from the French Ministry of Health and 
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Figure 2. Kaplan–Meier Curves for Composite Outcome of Death from Any Cause or Heart-Failure Events in the 
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Shown are the cumulative hazard rates of the two time-related clinical components of the composite primary out-
come — death from any cause or heart-failure events, which included rehospitalization for heart failure and worsen-
ing of heart failure during the initial hospitalization — in the cyclosporine group and the control group within 1 year 
in the modified as-treated population (i.e., patients who underwent randomization, received the study drug, and 
had valid data). This analysis did not include left ventricular remodeling. The inset shows the same data on an en-
larged y axis.
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